fda warning letters glp-1 compounding september 2025 Concerns Surrounding Compounded GLP-1s Mount As Shortages of Tirzepatide, Semaglutide End FDA Drug Recalls and Warnings:

Constipation, abdominal discomfort, and pain carried much lower discontinuation risk despite being commonly reported

For PT-141, the evidence is strongest: its FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder in women, and it has meaningful off-label use in men for erectile and libido issues that dont respond to PDE5 inhibitors

In the research literature on GHRH-plus-GHRP combinations, as well as in practitioner and community protocols, CJC-1295 (no-DAC) and Ipamorelin are frequently reported as being combined at a roughly 1:1 mass ratio

Per serving: ~220 cal | 26g protein | 4g fiber